Home › Cancro del polmone non a piccole cellule › Washington › Spokane
Studi clinici su Cancro del polmone non a piccole cellule a Spokane, WA
12 studi su Cancro del polmone non a piccole cellule cercano partecipanti presso sedi a Spokane e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
In reclutamentoFase 3
- Local Institution - 0384, Spokane
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
In reclutamentoFase 2
- Summit Cancer Centers, Spokane
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
In reclutamentoFase 2
- Medical Oncology Associates - Spokane /ID# 277172, Spokane
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
In reclutamentoFase 3
- Research Site, Spokane
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
In reclutamentoFase 3
- Summit Cancer Treatment Center, Spokane
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
In reclutamentoFase 1/2
- Providence Sacred Heart Medical Center, Spokane
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
In reclutamentoFase 1
- Summit Cancer Center, Spokane
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In
In reclutamentoFase 3
- Medical Oncology Associates - Summit Cancer Centers, Spokane
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
In reclutamentoFase 3
- MultiCare Deaconess Cancer and Blood Specialty Center - Downtown, Spokane
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
In reclutamentoFase 1
- Medical Oncology Associates, Spokane
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
In reclutamentoFase 2
- USA07-0, Spokane
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
In reclutamentoFase 1/2
- Research Site 105, Spokane
Studi su Cancro del polmone non a piccole cellule in altre città
- Houston, TX145 studi
- New York City, NY120 studi
- Arlington, VA104 studi
- Nashville, TN97 studi
- Boston, MA90 studi
- Los Angeles, CA87 studi
- St. Louis, MO73 studi
- Chicago, IL61 studi
- Baltimore, MD60 studi
- San Antonio, TX59 studi
- Columbus, OH56 studi
- Washington, DC55 studi
Altri studi a Spokane
- Cancro al seno8 studi
- Cancro ovarico8 studi
- Cancro colorettale8 studi
- Morbo di Parkinson7 studi
- Cancro alla prostata6 studi
- Leucemia linfatica cronica6 studi
- Carcinoma a cellule squamose della testa e del collo6 studi
- Cancro (tutti i tipi)6 studi
- Cancro al seno triplo negativo5 studi
- Melanoma5 studi
- Degenerazione maculare5 studi
- Atrofia geografica5 studi
Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.